≡

Cancerous Inhibitor Of PP2A (CIP2A)

[Edit]

p90; KIAA1524

Cancerous Inhibitor Of PP2A (CIP2A)
CCC R982
HGNC 29302
MGI 2146335
PubMed 24493623
RGD 1310335
UniProt Q8TCG1
Wiki KIAA1524
CIP2A has a calculated molecular mass of 102.2 kD and has a 255-amino acid coiled-coil region at its C terminus. Immunohistochemical analysis of human and mouse cells detected diffuse cytoplasmic p90 staining, with a slight concentration in the perinuclear region. Expression was high in embryonic day-17.5 and -18.5 mouse liver, and was moderate in embryonic brain, muscle, and epidermal layers. However, p90 was not expressed in adult mouse liver. KIAA1524 gene contains at least 26 exons and spans 92 kb. The 5-prime UTR is GC rich, and the 3-prime UTR contains 2 polyadenylation signals.anti-p90 autoantibodies in HCC, gastric cancer, and esophageal cancer patients. Expression of p90 was elevated in 6 of 11 gastric cancer tissues examined.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPR982Hu01 Recombinant Cancerous Inhibitor Of PP2A (CIP2A) Positive Control; Immunogen; SDS-PAGE; WB.
RPR982Hu02 Recombinant Cancerous Inhibitor Of PP2A (CIP2A) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies MAR982Hu21 Monoclonal Antibody to Cancerous Inhibitor Of PP2A (CIP2A) WB; IHC; ICC; IP.
PAR982Hu01 Polyclonal Antibody to Cancerous Inhibitor Of PP2A (CIP2A) WB; IHC; ICC; IP.
Assay Kits SER982Hu ELISA Kit for Cancerous Inhibitor Of PP2A (CIP2A) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Cancerous Inhibitor Of PP2A (CIP2A) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Cancerous Inhibitor Of PP2A (CIP2A) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Cancerous Inhibitor Of PP2A (CIP2A) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Cancerous Inhibitor Of PP2A (CIP2A) CLIA Kit Customized Service Offer
n/a ELISA Kit for Cancerous Inhibitor Of PP2A (CIP2A) ELISA Kit Customized Service Offer

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Cancerous Inhibitor Of PP2A (CIP2A) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Cancerous Inhibitor Of PP2A (CIP2A) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Cancerous Inhibitor Of PP2A (CIP2A) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Cancerous Inhibitor Of PP2A (CIP2A) CLIA Kit Customized Service Offer
n/a ELISA Kit for Cancerous Inhibitor Of PP2A (CIP2A) ELISA Kit Customized Service Offer
  1. "Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer."Oncogene 21:5006-5015(2002) [PubMed] [Europe PMC] [Abstract]
  2. "Prediction of the coding sequences of unidentified human genes. XVII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro."DNA Res. 7:143-150(2000) [PubMed] [Europe PMC] [Abstract]
  3. "The full-ORF clone resource of the German cDNA consortium."BMC Genomics 8:399-399(2007) [PubMed] [Europe PMC] [Abstract]
  4. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  5. "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
  6. "Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens."Prostate 63:252-258(2005) [PubMed] [Europe PMC] [Abstract]
  7. "CIP2A inhibits PP2A in human malignancies."Cell 130:51-62(2007) [PubMed] [Europe PMC] [Abstract]
  8. "Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle."Mol. Cell 31:438-448(2008) [PubMed] [Europe PMC] [Abstract]
  9. "Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach."Anal. Chem. 81:4493-4501(2009) [PubMed] [Europe PMC] [Abstract]
  10. "Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis."Sci. Signal. 3:RA3-RA3(2010) [PubMed] [Europe PMC] [Abstract]
  11. "Initial characterization of the human central proteome."BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]